Pfizer’s Phase 3 MagnetisMM-5 trial found that Elrexfio (elranatamab) significantly improved progression-free survival over a ...

Johnson & Johnson announced that it entered into a definitive agreement to acquire Atraverse Medical. Regeneron struck a drug pricing deal with the Trump administration to reduce prices on drugs for ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

Pfizer said on Wednesday its drug Elrexfio met the main goal in a ​late-stage trial that tested the blood cancer ‌treatment ...

US pharma giant Pfizer has announced positive topline results from the Phase III MagnetisMM-5 study of Elrexfio (elranatamab) ...

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Pfizer reported that its multiple myeloma therapy Elrexfio met the primary goal in a late-stage study, significantly extending progression-free survival for patients who had received at least one ...

Diagnosed with both AIDS and cancer, a writer finds solace in the Cape May surf and the profound gift of a friend truly engaging with his life’s work.

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...